TheraRadar
Clinical-Stage Companies / Abbisko Therapeutics

Abbisko Therapeutics

Pre-Approval PRO BETA
30
Total Trials
1
Phase 3
9
Phase 2
14
Recruiting
193
Score

Pipeline by Phase

Phase 3
1
Phase 2
9
Phase 1
22

Therapeutic Focus

Healthy Subjects Non-Small Cell Lung Cancer Pharmacokinetics Neoplasms Tenosynovial Giant Cell Tumor

Clinical Trials (30)

NCT05804045 Phase 3 ACTIVE NOT RECRUITING

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Started: 4/27/2023

NCT07327034 Phase 2 RECRUITING

ABSK-011+BSC vs. Placebo+BSC in Previously Treated Advanced HCC With FGF19 Overexpression

Started: 6/13/2025

NCT06668103 Phase 2 RECRUITING

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Started: 11/25/2024

NCT06632262 Phase 2 RECRUITING

A Phase 2 Clinical Study of ABSK061 and ABSK043

Started: 11/13/2024

NCT06111274 Phase 2 RECRUITING

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Started: 10/17/2023

NCT05441475 Phase 2 ENROLLING BY INVITATION

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab or SOC in HCC Patients

Started: 12/30/2021

NCT07164170 Phase 2 NOT YET RECRUITING

A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib

Started: 10/25/2025

NCT06186804 Phase 2 ENROLLING BY INVITATION

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

Started: 5/30/2023

NCT04906434 Phase 1 RECRUITING

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Started: 2/26/2020

NCT04192344 Phase 1 RECRUITING

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Started: 1/20/2020

NCT07417189 Phase 1 RECRUITING

A Phase I/II Study of ABSK141 in Patients With Advanced Solid Tumors ( ABSK141-101 )

Started: 3/2/2026

NCT07288957 Phase 1 RECRUITING

A Early Study of ABSK131 in Patients With Advanced/Metastatic Solid Tumors

Started: 7/22/2025

NCT07007546 Phase 1 RECRUITING

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABSK061 Mini-tablets in Healthy Adult Participants

Started: 5/17/2025

NCT05244551 Phase 1 RECRUITING

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Started: 6/30/2022

NCT06225804 Phase 1 RECRUITING

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Started: 2/22/2024

NCT07297875 Phase 1 NOT YET RECRUITING

A Study of ABSK061 to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy in Children With Achondroplasia

Started: 12/10/2025

NCT06306872 Phase 1 COMPLETED

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

Started: 2/23/2024

NCT07210996 Phase 1 COMPLETED

A Study to Evaluate the Relative Bioavailability of Pimicotinib Capsules Containing Free Base in Different Proportions in Healthy Subjects

Started: 9/12/2025

NCT05627063 Phase 1 ACTIVE NOT RECRUITING

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Started: 6/26/2023

NCT07126249 Phase 1 COMPLETED

A Study to Evaluate the the Bioequivalence of Two Different Pimicotinib Capsules in Healthy Subjects

Started: 5/13/2025

NCT06779253 Phase 1 COMPLETED

A Study to Investigate The Effect of Pimicotinib on The Pharmacokinetics of Metformin, Fexofenadine and Rosuvastatin In Healthy Subjects

Started: 3/14/2025

NCT06884072 Phase 1 ACTIVE NOT RECRUITING

A Study to Evaluate the Effect of a High-fat Meal on the Exposure of Pimicotinib Capsule in Healthy Subjects

Started: 4/8/2025

NCT06896760 Phase 1 NOT YET RECRUITING

A Mass Balance Study of [14C]ABSK011

Started: 4/7/2025

NCT06322706 Phase 1 COMPLETED

A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

Started: 3/22/2024

NCT06694948 Phase 1 COMPLETED

A Study to Evaluate the Relative Bioavailability of Two Different Pimicotinib Capsules in Healthy Subjects

Started: 12/10/2024

NCT06562946 Phase 1 COMPLETED

The Study to Assess the Pharmacokinetics of Pimicotinib in Subjects With Mild and Moderate Hepatic Impairment Relative to Subjects With Normal Hepatic Function

Started: 9/20/2024

NCT06186583 Phase 1 COMPLETED

A Mass Balance Study of [14C]ABSK021

Started: 12/13/2023

NCT06089733 Phase 1 COMPLETED

A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Started: 4/11/2023

NCT05280483 Phase 1 COMPLETED

ABSK021 Food Effect Study in Healthy Subjects

Started: 7/23/2022

NCT05533788 Phase 1 COMPLETED

ABSK091 Food Effect Study in Healthy Subjects

Started: 9/8/2020

Drug Candidates

ABSK-011 ABSK021 ABSK141-400mg ABSK141-Recommended Dose for Expansion (RDE) ABSK141-800mg ABSK141-1200mg ABSK141-Recommended Phase 2 dose (RP2D) ABSK-011 180 mg QD combined with atilizumab 1200 mg q3w ABSK-011 200mg BID combined with atilizumab 1200 mg q3w and bevacizumab 15mg/kg ABSK-011 200mg BID combined with toripalimab 240 mg and bevacizumab biosimilar 15 mg/kg
Activity Status: Active
Last Trial Started: 3/2/2026
Last Trial Ended: 10/16/2025
Trials (12 months): 8
Completed Trials: 11
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.